GlassScriptPhysician profile
Michael P Minning
NPI 1013974419
$5,254.40
in general payments reported to CMS, 2019-2025
45 companies · $767 in 2025
The $767 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $214 · 2021: $221 · 2022: $820 · 2023: $1,286 · 2024: $936 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,988.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $993.11 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $459.05 | 2019-2025 | Trintellix, Gattex |
| Novo Nordisk INC | $402.94 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $275.72 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $238.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $233.13 | 2019-2024 | Dificid, Gardasil 9, Vaxelis |
| Abbott Laboratories | $231.74 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $231.73 | 2019-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.63 | 2019-2025 | Jardiance, Ofev |
| Axsome Therapeutics, INC. | $167.10 | 2023-2025 | Auvelity |
| Allergan, INC. | $161.06 | 2019 | |
| Lilly USA, LLC | $148.23 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $136.97 | 2022-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $126.85 | 2019-2020 | |
| Tris Pharma INC | $111.35 | 2022-2025 | Dyanavel Xr |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Minning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.